NAD+
Nicotinamide Adenine Dinucleotide
BioSignal's overall confidence is measured: NAD+'s core biology is well established, but the evidence that boosting NAD+ delivers meaningful clinical benefits in healthy people remains limited.
How confident is BioSignal?
Our overall position, and how sure we are of it across each dimension — including where we are not sure at all.
Limited evidence
BioSignal's overall confidence is measured: NAD+'s core biology is well established, but the evidence that boosting NAD+ delivers meaningful clinical benefits in healthy people remains limited.
Early or sparse human evidence; conclusions remain uncertain.
Biological Role
NAD+'s role as a coenzyme in energy metabolism, DNA repair, and signaling is well established in foundational biochemistry.
Human Evidence
Human studies exist for several NAD+-boosting precursors, but many are small, short, or measure biomarkers rather than clinical outcomes.
Supplement Benefit
Precursors such as NR and NMN can raise NAD+ levels; whether that translates into consistent clinical benefit is still being established.
Longevity Claims
Evidence that raising NAD+ extends healthspan or lifespan in healthy humans is not established.
Safety Confidence
Short-term use of common precursors appears generally well tolerated in trials to date; long-term human safety data are limited.
Research Activity
NAD+ is an active, fast-moving research area spanning aging, metabolism, and neuroscience.
Where the evidence stands today
How mature the science is, what kinds of evidence exist, and — the part nobody else prints — what is still missing.
6/9
steps proven in humans
Partly established
3 steps not demonstrated: Large human RCTs · Clinical outcomes · Guideline / regulatory support
Guideline / regulatory support
Not shownNo guideline or regulatory approval for any indication.
Clinical outcomes
Not shownNo demonstrated clinical benefit in healthy humans — not for ageing, not for energy, not for cognition, not for longevity. The biomarker moves and the person does not.
Large human RCTs
Not shownNone. No adequately powered trial has tested whether raising NAD+ changes anything that matters.
Small human outcome trials
ProvenNumerous, small, and largely null on the outcomes people are buying it for.
Human safety data
ProvenGood in short-term trials. Long-term safety is unknown.
Human biomarker / pharmacology
ProvenNR and NMN measurably raise blood NAD+ in humans. The supplement does exactly what it says on the tin at this level — and this is where the evidence stops.
Animal
ProvenSubstantial, and genuinely striking in rodents — which is the source of nearly all the enthusiasm.
Cell / in vitro
ProvenExtensively characterised.
Mechanistic plausibility
ProvenNAD+ is central to cellular energy metabolism and to sirtuin and PARP activity, and it declines with age. The biology is textbook and it is not in dispute.
The bottom line
What we know, what we think, what we don't know — and what would change our mind.
What We Know
NAD+ is essential for cellular energy metabolism, mitochondrial function, DNA repair, and cellular signaling.
What We Think
Maintaining healthy NAD+ metabolism appears biologically important, but clinical benefits from NAD+-boosting strategies vary by intervention and remain under study.
What We Don't Know
It remains unclear whether increasing NAD+ produces meaningful long-term healthspan or longevity benefits in healthy humans.
Active Research
Current research is exploring NAD+ biology in aging, mitochondrial health, metabolic disease, neurodegeneration, and exercise physiology.
What Could Change Our Mind
Large, long-term randomized human trials showing meaningful clinical outcomes would materially change BioSignal's confidence.
The biggest myth
“NAD+ slows aging”
Preclinical work links NAD+ to aging biology, but there is no established evidence that supplementation slows aging in humans.
Ask BioSignal
Still have a question about nad+?
Answers are retrieved from this record and the rest of the knowledge graph — never generated.
Why people take nad+
Popularity is not evidence — but it is not stupid either. This explains the interest on its own terms.
NAD+ is the purest example in the BioSignal library of a beautiful mechanism outrunning its evidence. The biology is genuine — NAD+ really is central to cellular energy, it really does decline with age, and raising it really does produce remarkable effects in mice. Every step of that sentence is true, and none of it establishes that a person will benefit. The supplements demonstrably raise NAD+ in humans; what they have not done is change any outcome that a human would notice. People are interested because the story is one of the best in longevity science, and this record exists to show exactly where the story runs out.
If you're here because…
Jump straight to the part of the evidence that answers your question.
Approval, safety and regulatory
What it is approved for, who should be careful, what remains unknown — and the limits of what this evidence can tell you.
Regulatory status
Not an approved drug. Sold as dietary supplements (NR, NMN)
Availability
Over-the-counter supplements; regulatory status of NMN is contested in the US
Sport (WADA)
Not prohibited
Known safety profile
Common NAD+ precursors such as nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN) have been studied in short-term human trials and are generally reported as well tolerated at the doses studied.
Common issues
- Mild gastrointestinal discomfort
- Nausea
- Headache
- Flushing (more associated with high-dose niacin than with NR or NMN)
Use caution if
- People who are pregnant or breastfeeding
- People with active or prior cancer (NAD+ metabolism intersects with cell-growth pathways)
- People taking prescription medications
- Children and adolescents
Long-term unknowns
The long-term safety of sustained NAD+ elevation in healthy people has not been established. Effects over years of continuous use remain unknown.
Limits of this evidence
Most safety data come from small, short-duration studies. The absence of reported harm is not the same as proven long-term safety.
Demand, separated from evidence
Every claim people make about this, counted against what the evidence actually showed.
BioSignal evaluated 7 popular claims about nad+.
Here is where each one landed — including the claims of harm, where “not established” is reassuring rather than damning.
- Supported by evidence
- 1
- Mixed evidence
- 3
- Insufficient evidence
- 1
- Not established
- 2
Popularity is not evidence. This is simply a count of every claim BioSignal evaluated on this page, sorted by what the evidence actually showed — the full reasoning behind each verdict is in the Evidence Review below.
Supported by evidence
- NAD+ repairs DNA
Mixed evidence
- NAD+ improves energy
- NAD+ improves exercise performance
- NAD+ improves recovery
Insufficient evidence
- NAD+ improves cognition
Not established
- NAD+ slows aging
- NAD+ extends lifespan
The evidence review
Every claim with the reasoning behind its verdict, the doses actually studied, where scientists agree and disagree, and the questions still open.
What people claim
Every popular claim, with BioSignal’s verdict and how confident we are in it. The verdicts are always visible; open any claim to read the evidence behind it.
NAD+ improves energyMixedModerate confidence
Human evidence suggests possible improvements in selected metabolic measures, but consistent improvements in subjective energy have not been established.
NAD+ improves cognitionInsufficient evidenceLimited evidence
Human cognitive outcomes have been examined only in small or preliminary studies; an effect is not established.
NAD+ repairs DNASupportedHigh confidence
NAD+ is a required substrate for DNA-repair enzymes — its mechanistic role is well established. This does not, by itself, imply a clinical benefit from supplementation.
NAD+ improves exercise performanceMixedModerate confidence
Trials in athletic and older populations report inconsistent effects on performance, with no clear established benefit.
NAD+ extends lifespanNot establishedLimited evidence
Lifespan extension from raising NAD+ has been observed in some model organisms but has not been demonstrated in humans.
NAD+ improves recoveryMixedModerate confidence
Some studies report changes in recovery-related markers, but consistent clinical benefit is not established.
Doses used in human studies
What was actually given to participants in the research. These are descriptions of studies, not recommendations.
Healthy adults
- Intervention
- Oral nicotinamide riboside (NR)
- Dose
- ~250–1,000 mg/day
- Duration
- Weeks to a few months
- Outcome
- Blood NAD+ levels (biomarker)
- Notes
- Prototype — raises NAD+ biomarkers; clinical outcomes vary
Older adults
- Intervention
- Oral nicotinamide mononucleotide (NMN)
- Dose
- ~250–900 mg/day
- Duration
- Several weeks
- Outcome
- NAD+ biomarkers; physical measures
- Notes
- Prototype — early-stage human research
Clinical / varied
- Intervention
- Intravenous NAD+
- Dose
- Varies widely
- Duration
- Single or repeated sessions
- Outcome
- Tolerability; exploratory endpoints
- Notes
- Prototype — limited controlled data
Athletes
- Intervention
- Oral precursors
- Dose
- Study-dependent
- Duration
- Days to weeks
- Outcome
- Performance / recovery markers
- Notes
- Prototype — mixed results
Where scientists agree — and don’t
Agreed
- NAD+ is essential to core cellular metabolism and energy production.
- NAD+ is a required substrate for DNA-repair and signaling enzymes.
- Oral precursors (NR, NMN) can raise NAD+ biomarkers in humans.
Debated
- Whether raising NAD+ biomarkers produces consistent clinical benefits.
- Which precursor or route (oral vs intravenous) is most effective.
- The functional significance of age-related NAD+ decline in humans.
Unknown
- Whether NAD+ strategies affect long-term healthspan or lifespan in healthy people.
- Optimal dosing, and which populations benefit most.
- The long-term safety of sustained NAD+ elevation.
What remains unknown
- Do increases in NAD+ biomarkers translate into outcomes people can feel or measure clinically?
- Is there a meaningful long-term healthspan or longevity benefit in healthy humans?
- Which precursor, dose, and route — if any — is most effective?
- What are the effects of years of continuous use?
Questions people actually ask
What is NAD+?
NAD+ (nicotinamide adenine dinucleotide) is a coenzyme present in every living cell. It acts as a central carrier of electrons in metabolism and as a substrate for enzymes involved in DNA repair and cellular signaling. In short, it is one of the molecules that keeps basic cellular machinery running.
Why does NAD+ matter?
Because NAD+ participates in energy production, mitochondrial function, and DNA-repair signaling, healthy NAD+ metabolism is considered important for normal cell function. This biological centrality is why NAD+ has become a focus of aging and metabolic research — though biological importance alone does not establish that supplementation produces clinical benefit.
How is NAD+ studied?
NAD+ research spans several layers: biochemical and cell studies establish its molecular roles; animal models explore the effects of raising or lowering it; and human trials typically measure NAD+ levels in blood or tissue after giving precursors, sometimes alongside functional or clinical measures. Because methods and measurements differ between studies, results are not always directly comparable.
Does NAD+ decline with age?
Declines in NAD+ levels with age have been reported in preclinical models and some human tissues. The extent, consistency, and functional significance of these declines in healthy people are still being characterized, and measurement methods vary between studies.
How do NAD+ precursors differ (NR, NMN, IV)?
NAD+ itself is usually not taken directly; instead, precursors are used. Nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN) are oral precursors the body converts toward NAD+. Intravenous NAD+ delivers the molecule directly but has limited high-quality comparative human evidence. Which precursor or route is most effective for a given outcome is not established.
Why are results sometimes mixed?
Studies vary in population, dose, duration, the precursor used, and the outcomes measured — and many are small or short. Raising a biomarker like NAD+ does not automatically translate into a change people can feel or that appears on clinical measures. These differences help explain why findings across studies can look inconsistent.
Practical takeaways
- NAD+ is essential for cellular energy production and DNA repair.
- Its core biology is well established.
- Oral precursors can raise NAD+ biomarkers in humans.
- Long-term clinical benefits in healthy people remain uncertain.
- Larger, longer human trials are needed to draw firm conclusions.
How it works
The mechanism comes last on purpose. A compelling explanation of how something might work is the easiest part of the story to tell, and the part most likely to outlive the evidence for it.
NAD+'s role as a coenzyme in energy metabolism, DNA repair, and signaling is well established in foundational biochemistry.
How we found out
Foundational Biology
Decades of biochemistry established NAD+ as a central coenzyme in metabolism and redox reactions.
NAD+ and Aging Research
Research linked declining NAD+ levels with aspects of aging in preclinical models.
Human Precursor Studies
Early human trials began testing whether oral precursors can raise NAD+ levels safely.
Current Clinical Research
Ongoing studies examine clinical outcomes across metabolic, neurological, and aging-related contexts.
References
Verified sources. BioSignal does not print a citation it has not checked.
References for this record are being verified and will be published with the next review. BioSignal does not print citations it has not checked.
Version history
Version 0.1
Prototype Signal Record created for product development. Future versions will track scientific updates, evidence changes, and review history.
Continue exploring
Three places this record leads next.